BioPharm International - May 2024

BioPharm International - May 2024

Issue link: https://www.e-digitaleditions.com/i/1520706

Contents of this Issue

Navigation

Page 11 of 21

12 BioPharm International ® Partnerships for Outsourcing eBook May 2024 www.biopharminternational.com D rug development companies (sponsors) may assume a commitment to quality is inherent in the operations of every contract development and manufacturing organization (CDMO), simply because product quality is essential for ensur- ing patient safety. Certainly, every CDMO professes its commitment to quality. So, in evaluating potential part- ners to manufacture a drug or biologic, how can one accurately assess the CDMO's commitment to quality? The answer involves conducting a thorough on-site quality audit, asking the right questions, and request- ing detailed information. The answers, data, and docu- ments provided will reveal—by what they contain and what they omit—whether or not the CDMO has a strong quality management system and quality culture. Act like an FDA inspector A CDMO should welcome an on-site audit of its fa- cilities and operations as part of the vetting process. Reluctance to have an audit is a red f lag that some- thing is wrong. If the sponsor company is a small start-up or has lim- ited auditing experience, an experienced firm may be hired to conduct the inspection, ideally with the partici- pation of a member of the sponsor's own team. If the sponsor conducts the inspection, a great way to ensure all the bases are covered is to follow the FDA quality system inspection technique that the agency publishes for use by its own inspectors (1). The FDA guide describes how inspections should be performed on six systems—those related to quality, facilities and equip- ment, materials, production, packaging and labeling, and laboratory controls. The approach described should be adopted, and the following key questions should be asked and cer tain information requested. What is the structure of the quality team? A CDMO, like any pharmaceutical manufacturer, must How to Evaluate a CDMO's Commitment to Quality Ania Szymanska is site head of Quality at Scorpius Biomanufacturing. What do you need to ask during the vetting and selection process to ensure your clinical or commercial program won't be derailed by a quality-related problem? QUALITY STOCK ARTS - STOCK.ADOBE.COM

Articles in this issue

Links on this page

Archives of this issue

view archives of BioPharm International - May 2024 - BioPharm International - May 2024